New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
18:31 EDTTCPC, AFOP, DRI, AMKR, EMN, HLF, MAS, HLS, PCL, ARWR, IDTI, CGNXOn The Fly: After Hours Movers
UP AFTER EARNINGS: Cognex (CGNX), up 16.4% after reporting second quarter results and third quarter revenue guidance above analyst expectations... HealthSouth (HLS), up 7.4% after reporting second quarter results and increasing fiscal 2014 EPS and Adjusted EBITDA guidance... Amkor Technology (AMKR), up 6.4%... Integrated Device (IDTI), up 7.6% after reporting first quarter results... Masco (MAS), up 4.8%. ALSO HIGHER: Darden Restaurants (DRI), up 4.6% following the company's announcement that chairman and CEO Clarence Otis will step down and the board will separate the chairman and CEO roles, appointing lead independent director Charles Ledsinger, Jr., as independent non-executive chairman... Arrowhead Research (ARWR), up 16.5% following positive comments made by CEO Christopher Anzalone, Ph.D. in an interview on CNBC. DOWN AFTER EARNINGS: Herbalife (HLF), down 11.5% after reporting disappointing second quarter results and giving guidance for the third quarter and fiscal 2014... Alliance Fiber Optic (AFOP), down 9.7%... Plum Creek Timber (PCL), down 2.8%... Eastman Chemical (EMN), down fractionally after reporting quarterly results. ALSO LOWER: TCP Capital (TCPC), down 3.1% after filing to sell $5.4M shares of common stock.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
November 18, 2015
06:19 EDTCGNXCognex upgraded to Buy from Hold at Canaccord
Subscribe for More Information
November 17, 2015
16:42 EDTHLFJustice Department announces criminal charges against supplement maker USPlabs
The U.S. Department of Justice, along with partners at the Food and Drug Administration, Federal Trade Commission, Postal Inspection Service, and Internal Revenue Service, announced a "nationwide sweep" targeting more than 100 makers and marketers of dietary supplements. The agencies noted, "The actions discussed today resulted from a year-long effort, beginning in November 2014, to focus enforcement resources in an area of the dietary supplement market that is causing increasing concern among health officials nationwide. In each case, the department or one of its federal partners allege the sale of supplements that contain ingredients other than those listed on the product label or the sale of products that make health or disease treatment claims that are unsupported by adequate scientific evidence." Among the cases announced Tuesday is a criminal case charging USPlabs and several of its corporate officers with various counts associated with the unlawful sale of dietary supplements, obstruction of an FDA proceeding, and conspiracy to commit money laundering. The Department also filed in the past week five civil cases seeking injunctive relief against a number of businesses and individuals that allegedly sold supplements as disease cures or that were otherwise in violation of the law. The cases involve various entities, including Vibrant Life, Viruxo, Optimum Health, Bethel Nutritional, VivaCeuticals, and Regeneca, said the agency. Note that shares of GNC (GNC), Herbalife (HLF), Vitamin Shoppe (VSI), and Natural Health (NHTC) all slipped Tuesday following early reports of criminal charges in the dietary supplement space. Reference Link
15:10 EDTHLFDOJ files indictment against USPLabs over Supplements, FDA Law Blog says
Shares of GNC Holdings (GNC), Vitamin Shoppe (VSI), and Herbalife (HLF) were all weak this afternoon on concerns that they would be the target of the FDA's action. Reference Link
13:09 EDTHLFHerbalife says not aware of being named in DOJ supplement action, Bloomberg says
Subscribe for More Information
12:35 EDTHLFHerbalife puts active on headlines of DOJ briefing on supplement actions
Herbalife November 47 and 50 puts are active on total put volume of 9,800 contracts (2,400 calls) following Bloomberg headlines of DOJ briefing on supplement actions. November put option implied volatility is at 113, December is at 55; compared to its 52-week range of 34 to 126. Active put volume suggests traders taking positions for wide price movement.
12:28 EDTHLFGNC, Vitamin Shoppe, Herbalife at lows following DOJ supplement advisory
The Department of Justice said in a media advisory that it plans to announce at 3:30 pm today its actions related to dietary supplements sales and unlawful ads. Following the press advisory, shares of GNC Holdings (GNC), Vitamin Shoppe (VSI) and Herbalife (HLF) are at session lows, though none of the companies were named in the advisory.
10:00 EDTPCLOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: CF Industries (CF) upgraded to Positive at Susquehanna... ExlService (EXLS) upgraded to Buy from Neutral at BofA/Merrill... Fitbit (FIT) upgraded to Buy at BofA/Merrill... Forward Air (FWRD) upgraded to Outperform at Baird... HD Supply (HDS) upgraded to Positive from Neutral at Susquehanna... Hannover Re (HVRRY) upgraded to Overweight from Underweight at JPMorgan... Moody's (MCO) upgraded to Buy from Neutral at UBS... PRA Group (PRAA) upgraded to Strong Buy from Market Perform at Raymond James... Plum Creek Timber (PCL) upgraded to Outperform from Sector Perform at RBC Capital... Shire (SHPG) upgraded to Outperform from Market Perform at Leerink... Yandex (YNDX) upgraded to Overweight from Equal Weight at Morgan Stanley... Zayo Group (ZAYO) upgraded to Buy from Neutral at MoffettNathanson.
07:47 EDTTCPCWells Fargo to hold a forum
Subscribe for More Information
06:20 EDTPCLPlum Creek Timber upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital upgraded Plum Creek Timber (PCL) to Outperform and increased its price target to $56 from $42 on shares following the acquisition by Weyerhaeuser (WY). Analyst Paul Chan likes the merger and said synergies, increased liquidity, and broadened timberlands diversity will make the combined company the investment of choice for investors seeking exposure to the group.
November 16, 2015
17:10 EDTHLFSoros took stake in Paypal, liquidated Herbalife stake
Soros Fund Management gave a quarterly update on its stakes in a filing this afternoon. NEW STAKES: Paypal (PYPL), CIT Group (CIT), Schlumberger (SLB), Kraft Heinz (KHC), and Amazon (AMZN). INCREASED STAKES: Allergan (AGN), Lions Gate (LGF), Energen (EGN), Southwest Airlines (LUV), and Qunar Cayman Islands (QUNR). DECREASED STAKES: LyondellBasell (LYB), YPF (YPF), Time Warner Cable (TWC), Dow Chemical (DOW), and Monsanto (MON). LIQUIDATED STAKES: Herbalife (HLF), Lennar (LEN), DR Horton (DHI), United Continental (UAL), and Nice Systems (NICE).
11:09 EDTARWRArrowhead says data shows ARC-520 can produce reductions of HBV antigens
Arrowhead Research Corporation presented data from a Phase 2a clinical study at The AASLD Liver Meeting 2015 demonstrating that ARC-520, its lead drug candidate against chronic hepatitis B infection, effectively reduced HBV viral antigens derived from cccDNA. HBV surface antigen was reduced substantially with a maximum reduction of 1.9 logs and a mean maximum reduction of 1.5 logs in treatment naive e-antigen-positive patients. This direct antiviral effect was still evident 57 days after a single dose. These data strongly support advancement of ARC-520, and Arrowhead has initiated multiple studies aimed at producing a functional cure of HBV. In this presentation, Dr. Yuen and co-authors show that in the Heparc-2001 clinical study, ARC-520 in combination with entecavir achieved maximum reductions of HBsAg, HBV DNA, HBeAg, and core-related antigen of 1.9 logs, 4.3 logs, 1.7 logs, and 1.2 logs, respectively. Consistent with findings from Arrowhead's chimpanzee study, also presented at AASLD, variations in viral antigen reduction indicated that patients previously treated with chronic entecavir and patients that were treatment-naive and negative for HBeAg likely had lower levels of cccDNA derived mRNA transcripts. As such, HBeAg-positive treatment naive patients experienced a greater relative reduction in HBsAg than patients that were HBeAg-negative or treatment experienced. One transitional patient in cohort 7 was HBeAg-positive at baseline and became HBeAg-negative at days 3 to 43. This patient experienced an intermediate response initially, however HBsAg continued to trend downward through day 57, the last time-point available. ARC-520 was well tolerated with no serious adverse events, no dose limiting toxicities, no discontinuations due to medication AEs, and a modest occurrence rate of AEs that were all deemed unrelated to study drug by the principal investigator. No AE occurred more than once. There were no AEs amongst 10 patients receiving placebo. There was a low occurrence rate of abnormal laboratory tests, with no observed relationship to timing or dose.
08:59 EDTPCLPlum Creek Timber price target raised to $58 from $46 at DA Davidson
Subscribe for More Information
08:27 EDTARWRArrowhead to hold an analyst and investor reception
Management hosts an Analyst and Investor Reception to discuss ARC-520 and key data presented at the 66th Annual Meeting of AASLD in San Francisco on November 16 at 9:30 pm. Webcast Link
November 15, 2015
18:28 EDTARWRArrowhead reports data on anti-hepatitis B effects of ARC-520 in chimpanzees
Arrowhead announced the presentation of data demonstrating that ARC-520, its drug candidate against chronic hepatitis B infection, leads to "robust, sustained anti-viral effects in chimpanzees with chronic HBV," according to the company. Arrowhead also reported a new discovery that HBV DNA integrated into the host genome is "likely an important source of HBV surface antigen production, particularly in chimps that are negative for hepatitis B e-antigen." ARC-520 led to a drop in circulating HBsAg, with the degree of HBsAg reduction correlating with HBeAg status. HBeAg-positive and negative chimps demonstrated HBsAg reductions of 96.8%-99.8% and 68.4%-87.4%, respectively, with an intermediate response in a chimp transitioning from HBeAg positive to negative. In addition, one chimp seroconverted for HBeAg during ARC-520 therapy and had a sustained virologic response with respect to HBeAg, HBV DNA, and HBsAg. This persisted off therapy and through at least 32 weeks after ARC-520 and NUC therapy was removed. A second chimp demonstrated effects consistent with immunologic reactivation. Arrowhead also found that the predominant form of liver HBV DNA differed in HBeAg-negative versus HBeAg-positive chimps. Most HBV DNA in HBeAg-positive chimps was cccDNA, while less than 5% of HBV DNA in HBeAg-negative chimps was cccDNA. In addition, HBV RNA profiles in HBeAg-negative chimps were consistent with transcripts arising from integrated DNA. "These data and others, strongly suggest that integrated DNA is likely an important source of HBsAg production in HBeAg-negative chimps," claimed the company. "Direct confirmatory data" was obtained by treating HBeAg negative chimps with a siRNA designed to target transcripts originating from integrated HBV DNA. Up to an additional 99% of HBsAg knockdown was achieved, resulting in overall relative knockdown levels similar to those observed using ARC-520 in HBeAg-positive chimps. Arrowhead said it has incorporated one of these RNAi triggers and one targeting predominantly cccDNA derived transcripts into a new complementary drug candidate, ARC-521, that is planned to be in clinical trials in 2016. The company noted it plans to present additional data at the Hep Dart conference in December demonstrating that two of four HBeAg-positive chimps exhibited signs of immune reactivation, "which is believed to be a necessary step toward achieving a functional cure of HBV."
13:45 EDTPCLWeyerhaeuser shares could return 40% in a year, Barron's says
Subscribe for More Information
November 13, 2015
16:40 EDTMASAppaloosa gives quarterly update on stakes
Subscribe for More Information
08:28 EDTARWRAmerican Association for Study of Liver Diseases to hold annual meeting
The Liver Meeting 2015 is being held in San Francisco on November 13-17.
November 12, 2015
07:14 EDTDRIDarden sales trends outperforming, says Oppenheimer
Subscribe for More Information
November 11, 2015
10:00 EDTCGNXOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Albemarle (ALB) initiated with a Neutral at UBS... Ares Management (ARES) reinstated with an Overweight at JPMorgan... Cablevision (CVC) initiated with a Neutral at SunTrust... Canadian Solar (CSIQ) initiated with an Overweight at Morgan Stanley... Carriage Services (CSV) initiated with an Outperform at Oppenheimer... Charter (CHTR) initiated with a Buy at SunTrust... Cognex (CGNX) initiated with a Market Perform at FBR Capital... Comcast (CMCSA) initiated with a Neutral at SunTrust... CubeSmart (CUBE) initiated with a Buy at BB&T... Extra Space Storage (EXR) initiated with an Underweight at BB&T... FARO Technologies (FARO) initiated with a Market Perform at FBR Capital... IPG Photonics (IPGP) initiated with an Outperform at FBR Capital... NeuroDerm (NDRM) initiated with an Outperform at Raymond James... Perceptron (PRCP) initiated with an Outperform at FBR Capital... Proteon Therapeutics (PRTO) initiated with an Outperform at Raymond James... Public Storage (PSA) initiated with an Underweight at BB&T... Pure Storage (PSTG) initiated with a Neutral at Sterne Agee CRT... Service Corp. (SCI) initiated with an Outperform at Oppenheimer... Sovran Self Storage (SSS) initiated with a Buy at BB&T... Time Warner Cable (TWC) initiated with a Neutral at SunTrust.
09:02 EDTCGNXCognex initiated with a Market Perform at FBR Capital
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use